Braftovi

Generic name: encorafenib

Used for: Advanced melanoma with a BRAF mutation · Colorectal cancer that has spread, with a BRAF mutation · Non-small cell lung cancer that has spread, with a BRAF mutation · 2 more

How do you pay?

How to pay the least

Ask for the cash price

Braftovi

We didn’t find one.

  1. Ask your pharmacy for Braftovi’s cash price, and one or two other pharmacies too.
  2. Braftovi’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Pfizer Patient Assistance Program. Meet the income requirements – Your annual household pre-tax income cannot exceed 300% of the Federal Poverty Level, adjusted for household size. Or call 1-844-989-7284.

See if you qualify 

Compare every option

Question
Brand nameBraftovi
Authorized genericencorafenib
Regular genericencorafenib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Braftovi?
The original
–
–

Brand nameThe maker’s card

Pfizer Oncology Together Co-Pay Savings Program

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $10,600 a year off your co-pay.

Sign up on pfizeroncologytogether.com 

Or call 1-877-744-5675. See the offer on braftovi.com

In the maker’s words

“Eligible, commercially insured patients may pay as little as $0 per month for their Pfizer Oncology treatment.”

From the maker’s offer on braftovi.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Braftovi itself, from the same company, sold without the brand name, and usually for less. For now Braftovi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

BRAFTOVI is a kinase inhibitor indicated:

Melanoma

  • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test.

Colorectal Cancer (CRC)

  • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorized test.
  • in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-authorized test, after prior therapy.

Non-Small Cell Lung Cancer (NSCLC)

  • in combination with binimetinib, for the treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test.

Limitations of Use

BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.

Source: the FDA label for Braftovi (Array BioPharma Inc.), February 26, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/braftovi/